Strategic funding AN2 Therapeutics has secured substantial funding ($202M) and recent private placement ($40M), signaling strong investor confidence and near-term availability of capital to accelerate pipeline activities, making them a viable partner for collaboration and licensing discussions.

Phase 2 momentum With three Phase 2 studies active in 2026 across hematologic, infectious, and oncology targets, there are multiple near-term collaboration and co-development opportunities, particularly for partners seeking to leverage boron-chemistry inspired small molecules.

Disease focus Strategic emphasis on tuberculosis, malaria, and Mycobacterium abscessus Complex lung disease, plus broader infectious disease programs, presents BD opportunities with health systems, grants, and consortia focused on global TB/Malaria elimination and niche pulmonary infections.

Strategic partnerships Recent Open Market Sale Agreement with Jefferies enabling up to $80M in at-the-market issuances suggests readiness for scalable equity-backed financings to support pipeline expansion, co-development deals, or milestone-driven partnerships.

Clinical collaboration Active investigator-initiated trials and ongoing clinical development in oncology and bone/infectious disease targets create avenues for research collaborations, sponsored trials, and access to academic networks for joint data generation and strategic alignment.